US Stock MarketDetailed Quotes

AIM AIM ImmunoTech

Watchlist
  • 0.1290
  • -0.0096-6.93%
Close Feb 14 16:00 ET
  • 0.1242
  • -0.0048-3.72%
Post 20:01 ET
8.87MMarket Cap-0.27P/E (TTM)

About AIM ImmunoTech Company

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Company Profile

SymbolAIM
Company NameAIM ImmunoTech
Listing DateJul 19, 1996
Founded1966
CEOMr. Thomas K. Equels, Esq.
MarketAMEX
Employees28
Fiscal Year Ends12-31
Address2117 SW Highway 484
CityOcala
ProvinceFlorida
CountryUnited States of America
Zip Code34473
Phone1-352-448-7797

Company Executives

  • Name
  • Position
  • Salary
  • Thomas K. Equels, Esq.
  • Executive Vice Chairman of the Board, Chief Executive Officer and President
  • 1.08M
  • Robert Dickey, IV
  • Chief Financial Officer
  • 64.48K
  • Peter W. Rodino, III
  • Chief Operating Officer, General Counsel & Secretary
  • 527.64K
  • Dr. William M. Mitchell, M.D.,PhD
  • Chairman of the Board
  • 139.37K
  • Nancy K. Bryan
  • Independent Director
  • 93.75K
  • Stewart L. Appelrouth
  • Independent Director
  • 139.37K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More